Onlay Synthetic Bioabsorbable Mesh Herniorrhaphy Versus Herniorrhaphy Only in the Primary Treatment of Large Hiatal Hernia
HIATUS
1 other identifier
interventional
256
1 country
26
Brief Summary
The large hiatal hernia (LHH) now represents approximately 50% of laparoscopic antireflux surgical practice. In a non-comparative retrospective study of 399 patients operated for LHH with onlay patch of a bioprosthetic absorbable (Gore® Bio-A® HH0710) mesh with a mean follow-up of 44 months, 16% had a symptomatic recurrence with 7,9% requiring reoperation, one patient had oesophageal stenosis. No comparative effectiveness data exist to date. Hypothesis: the incidence of postoperative hiatus hernia would be reduced by the addition of biosynthetic absorbable mesh reinforcement to a standardized suture repair technique, as compared to laparoscopic repair without mesh, without increasing the risk of complications. The main objective is to compare the radiologic recurrence rate at 2 years between standardized herniorrhaphy with onlay biosynthetic absorbable mesh repair versus standardized herniorrhaphy with no mesh in symptomatic LHH.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2024
Longer than P75 for not_applicable
26 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 30, 2022
CompletedFirst Posted
Study publicly available on registry
May 19, 2023
CompletedStudy Start
First participant enrolled
January 15, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 18, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 18, 2028
January 18, 2024
January 1, 2024
4 years
December 30, 2022
January 17, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Large Hiatal Hernia recurrence
Radiologic recurrence will be identified at 24 months by an experienced radiologist blinded to the result of randomization and defined as the presence of any abdominal content located above the level of the diaphragm on CT-scan.
Month 24
Secondary Outcomes (34)
Evaluation of Quality of life (QoL) by GIQLI,
Day 0
Evaluation of Quality of life (QoL) by GIQLI,
Month 1
Evaluation of Quality of life (QoL) by GIQLI,
Month 6
Evaluation of Quality of life (QoL) by GIQLI,
Month 12
Evaluation of Quality of life (QoL) by GIQLI,
Month 24
- +29 more secondary outcomes
Study Arms (2)
Biosynthetic absorbable mesh
EXPERIMENTALPatients who have undergone hiatal surgery with use of a biosynthetic absorbable mesh
No biosynthetic absorbable mesh
SHAM COMPARATORPatients who have undergone hiatal surgery without use of a biosynthetic absorbable mesh
Interventions
laparoscopic hiatal hernia repair has replaced the traditional laparotomic or thoracotomic approach, and has resulted in a reduction of length of hospital stay and morbidity, and increased patients' acceptance
Eligibility Criteria
You may qualify if:
- Patient undergoing laparoscopic primary repair for symptomatic LHH. LHH is defined as a hiatal hernia larger than 5 cm in axial length as diagnosed at barium series and/or CT-scan with contrast swallow and/or CT-scan with contrast injection with axial reconstruction.
- Patient aged ≥ 18 years;
- Patient affiliated to a social security system or beneficiary of the same;
You may not qualify if:
- Patient undergoing reoperation for recurrent LHH repair;
- Emergency presentation needing an operation in a delay \<6 hours;
- Asymptomatic hiatal hernia;
- American anesthesiologist score \>3;
- Recurrent hiatal hernia and previous surgical interventions involving gastroesophageal junction;
- Brachyesophagus defined as the impossibility to achieve an intraabdominal length of the esophagus of at least 3cm after reduction of hernia contents and complete dissection and resection of the hernia sac;
- Previous major upper gastrointestinal surgery;
- Inability to perform primary closure of the crura;
- Pregnant or breast-feeding woman;
- Persons deprived of liberty or under guardianship or incapable of giving consent;
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol or follow-up schedule, as assessed by investigator.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (26)
CH de la Côte Basque
Bayonne, 64100, France
Hôpital Jean Minjoz, CHRU de Besançon
Besançon, 25000, France
Hôpital Cavale blanche, CHRU de Brest
Brest, 29000, France
Hôpital Côte de nacre, CHU Caen Normandie
Caen, 14000, France
Hôpital Estang
Clermont-Ferrand, 63000, France
Hôpital Louis-Mourier, AP-HP
Colombes, 92700, France
Hôpital Nord, CHU de Grenoble
La Tronche, 38700, France
Hôpital Claude Huriez, CHRU de Lille
Lille, 59000, France
Polyclinique du bois, Hôpital privé Le Bois
Lille, 5900, France
Hôpital Dupuytren 1, CHU de Limoges
Limoges, 87000, France
Hôpital de la Croix-Rousse, HCL
Lyon, 69000, France
Hôpital Saint Eloi, CHU de Montpellier
Montpellier, 34000, France
Hôpital Hôtel Dieu, CHU de Nantes
Nantes, 44000, France
Hôpital Archet, CHU de Nice
Nice, 06000, France
Hôpital Saint-Louis, AP-HP
Paris, 75010, France
Hôpital Saint-Antoine, AP-HP
Paris, 75012, France
DMU SAPERE, CHU Pitié-Salpêtrière APHP
Paris, 75013, France
Institut Mutualiste Montsouris
Paris, 75014, France
Hôpital Bichat, AP-HP
Paris, 75018, France
Hôpital du Haut Lévêque
Pessac, 33600, France
Hôpital Jean-Bernard, CHU de Poitiers
Poitiers, 86000, France
CH René-Dubos
Pontoise, 95000, France
CHU de Rennes, Site PONTCHAILLOU
Rennes, 35000, France
Hôpital Charles Nicolle, CHU de Rouen
Rouen, 76000, France
Hôpital Felix-Guyon, CHU de la Réunion
Saint-Paul, 97415, France
Hôpital Rangueil, CHU de Toulouse
Toulouse, 31000, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Caroline Gronnier, MD, PhD
University Hospital, Bordeaux
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, CARE PROVIDER
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 30, 2022
First Posted
May 19, 2023
Study Start
January 15, 2024
Primary Completion (Estimated)
January 18, 2028
Study Completion (Estimated)
January 18, 2028
Last Updated
January 18, 2024
Record last verified: 2024-01
Data Sharing
- IPD Sharing
- Will not share